Generic Name and Formulations:
Menotropins (follicle-stimulating hormone 75 IU + luteinizing hormone 75 IU); per vial; lyophilized pwd for SC inj after reconstitution.
Ferring Pharmaceuticals, Inc.
Indications for MENOPUR:
Stimulation of multiple follicles in ovulatory patients undergoing Assisted Reproductive Technologies (ART) who have previously received pituitary suppression.
Individualize. Use lowest effective dose. Initially 225 IU SC inj daily for 5 days starting on Day 2 or 3 of cycle; or, may be given in combination with Bravelle (total initial dose: max 225 IU [Menopur 150 IU + Bravelle 75 IU; or Menopur 75 IU + Bravelle 150 IU]). Adjust dose based on response in increments of up to 150 IU at intervals of at least 2 days; max 450 IU daily; usual max 20 days. Induce final maturation/ovulation of follicles with hCG (see Precautions).
Primary ovarian failure. Uncontrolled non-gonadal endocrinopathies (eg, thyroid, adrenal, pituitary). Undiagnosed abnormal uterine bleeding. Ovarian cysts or enlargement. Tumor of pituitary, hypothalamus, breast, ovary, or uterus. Pregnancy (Cat.X).
Do complete gynecological and endocrinological exam first. Risk of ovarian hyperstimulation syndrome (OHSS); monitor for at least 2 weeks after hCG administration. Discontinue if severe OHSS occurs; consider hospitalization (see full labeling). Abnormal ovarian enlargement; monitor ovarian response and/or measure serum estradiol levels. Do not give hCG if abnormally enlarged ovaries on last day of Menopur therapy to reduce OHSS development. Increased risk of thromboembolic events in severe obesity, thrombophilia, pregnancy, personal or family history of thrombosis. Nursing mothers: not recommended.
Abdominal cramps/pain, abdomen enlarged, headache, nausea, inj site reactions; ovarian enlargement or cysts, OHSS, thromboembolic events, ovarian torsion, multi-fetal gestation and birth, ectopic pregnancy, spontaneous abortion, ovarian neoplasms, risk of congenital malformations, hypersensitivity reactions.
Vials—5 (w. diluent)
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Managing Immune-Related Adverse Events
- PD-1/PD-L1 Inhibitors May Increase the Risk of Hyperprogressive Disease in NSCLC
- Predicting Response to Immunotherapy in Late-Stage Melanoma
- Genetic Counseling Recommended for Advanced Prostate Cancer
- A Simplified Dose Schedule of Cetuximab as a Maintenance Therapy in Head and Neck Cancer May Reduce Drug Toxicities
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- Transplant Status May Affect CAR-T Therapy Outcomes in CLL and B-ALL
- Study Zeroes in on Cause of Castration-Resistant Prostate Cancer
- Beyond BRCA: New Predisposition Genes Linked to Breast, Ovarian Cancers
- "Impressive" CNS Responses With Osimertinib Compared With Standard EGFR-TKIs in Patients With CNS Metastases at Baseline